» Articles » PMID: 38481514

Development of a Kidney Prognostic Score in a Japanese Cohort of Patients With Antineutrophil Cytoplasmic Autoantibody Vasculitis

Abstract

Introduction: Glomerulonephritis is frequent in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and crucial to disease outcomes. We conducted a detailed assessment of renal pathology in Japanese patients with AAV, and developed a new score that would predict renal outcome.

Methods: Two hundred twenty-one patients who were diagnosed with AAV and underwent a kidney biopsy were enrolled. Data on glomerular, tubular, interstitial, and vascular lesions from kidney biopsies were analyzed; the 3 established classification and prognostic scoring systems (Berden Classification, Mayo Clinic/RPS Chronicity Score [MCCS], and ANCA Renal Risk Score [ARRS]) were validated. Further, we developed a new prognostic score by including variables relevant for Japanese patients with ANCA-glomerulonephritis.

Results: Median follow-up was 60 months (interquartile range: 6-60). End-stage kidney disease (ESKD) risk prediction by the MCCS and the ARRS was confirmed. Moreover, our analysis identified 4 items with significant ESKD risk prediction capacity, namely percentage of cellular, fibrocellular, and fibrous crescents; and sclerotic glomeruli. Based on our findings, we created a score evaluating the percentage of these lesions to total glomeruli, the Percentage of ANCA Crescentic Score (PACS). The area under the receiver operating characteristic (ROC) curve evaluating PACS was 0.783. The PACS had a comparable performance as the ARRS in predicting ESKD. The optimal PACS cut-off for ESKD risk over 60 months was 43%. In addition, the percentage of cellular crescents and presence of interstitial inflammation were independent predictors of kidney function recovery.

Conclusion: We developed a new score predicting renal prognosis using histopathological data of Japanese patients with ANCA-glomerulonephritis. Studies are needed to validate our results in international cohorts.

Citing Articles

ANCA-Associated Glomerulonephritis: Diagnosis and Therapy Proceedings of the Henry Shavelle Lectureship.

Ivkovic V, Windpessl M, Berke I, Geetha D, Callemeyn J, Norouzi S Glomerular Dis. 2025; 5(1):26-47.

PMID: 39991195 PMC: 11842095. DOI: 10.1159/000542925.


Prognosis of microscopic polyangiitis is well predictable in the first 2 weeks of treatment.

Owaki A, Tanaka A, Furuhashi K, Watanabe Y, Koshi-Ito E, Imaizumi T Clin Exp Nephrol. 2024; 28(7):701-706.

PMID: 38851645 PMC: 11189982. DOI: 10.1007/s10157-024-02522-6.

References
1.
Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

2.
Racusen L, Solez K, Colvin R, Bonsib S, Castro M, CAVALLO T . The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55(2):713-23. DOI: 10.1046/j.1523-1755.1999.00299.x. View

3.
Yoshida S, Hanai S, Nakagomi D, Kobayashi K, Takahashi K, Furuya F . Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab. Intern Med. 2020; 60(1):145-150. PMC: 7835465. DOI: 10.2169/internalmedicine.4752-20. View

4.
Furuta S, Chaudhry A, Hamano Y, Fujimoto S, Nagafuchi H, Makino H . Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 2014; 41(2):325-33. DOI: 10.3899/jrheum.130602. View

5.
Suppiah R, Robson J, Grayson P, Ponte C, Craven A, Khalid S . 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis Rheumatol. 2022; 74(3):400-406. DOI: 10.1002/art.41983. View